Creative Planning’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Creative Planning’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-764	Closed	-$18K	–	2048
2017 Q2	$18K	Hold	764	–	–	﹤0.01%	3239
2017 Q1	$18K	Hold	764	–	–	﹤0.01%	3186
2016 Q4	$14K	Sell	764 -100	-12%	-$2K	﹤0.01%	3299
2016 Q3	$20K	Hold	864	–	–	﹤0.01%	3057
2016 Q2	$16K	Hold	864	–	–	﹤0.01%	2935
2016 Q1	$16K	Hold	864	–	–	﹤0.01%	2901
2015 Q4	$25K	Sell	864 -100	-10%	-$2.89K	﹤0.01%	2666
2015 Q3	$25K	Buy	+964	New	+$32.6K	﹤0.01%	2546
2015 Q2	–	Sell	-200	Closed	-$7K	–	1263
2015 Q1	$7K	Buy	+200	New	+$6.11K	﹤0.01%	3376

Other funds holding BBC

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Cardan Capital Partners Denver, Colorado $893M AUM 22.82% 1-Year Est. Return

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Avior Wealth Management Omaha, Nebraska $3.79B AUM 15.36% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Creative Planning's BBC Position: Q3 2017 in Review

Creative Planning sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q3 2017, closing a stake of 764 shares — an estimated $18K sold.

Creative Planning first reported a position in BBC in Q1 2015 and held it in 9 quarters. The position peaked at $25K in Q4 2015. 10 funds tracked by Wall St. Rank hold BBC as of Q3 2017.

Creative Planning reported no remaining Virtus Biotech Clinical Trials ETF position as of Q3 2017 after selling out during the quarter.
Creative Planning sold 764 Virtus Biotech Clinical Trials ETF shares in Q3 2017, an estimated $18K.
Creative Planning first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2015 and held it in 9 quarters.
Creative Planning's Virtus Biotech Clinical Trials ETF position peaked at $25K in Q4 2015.
10 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.